{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=6", "query": { "intervention": "enfortumab vedotin", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 70, "total_pages": 7, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=enfortumab+vedotin&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-21T18:40:56.877Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07183319", "title": "Circulating Tumor DNA Response In Urothelial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Pembrolizumab & Enfortumab Vedotin (PEV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Oklahoma", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2026-01-19", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-02-02", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 1, "location_summary": "Oklahoma City, Oklahoma", "locations": [ { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07183319" }, { "nct_id": "NCT07390617", "title": "A Study of Neuropathy Caused by Enfortumab Vedotin in People With Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Neuropathy", "Urothelial Carcinoma", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Non-therapeutic Nerve Conduction Studies", "type": "OTHER" }, { "name": "Non-therapeutic assessment of patient-reported neuropathy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2026-01-20", "completion_date": "2028-01-20", "has_results": false, "last_update_posted_date": "2026-05-29", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07390617" }, { "nct_id": "NCT05126472", "title": "Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-muscle Invasive Bladder Cancer" ], "interventions": [ { "name": "anti-CD40 antibody 2141-V11", "type": "DRUG" }, { "name": "Intravesical Gemcitabine", "type": "DRUG" }, { "name": "Intravesical Gemcitabine with anti-CD40 antibody 2141-V11", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 115, "start_date": "2021-11-08", "completion_date": "2027-11", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05126472" }, { "nct_id": "NCT07217496", "title": "N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Urothelial Cancer", "Bladder Cancer" ], "interventions": [ { "name": "Nogapendekin Alfa Inbakicept (NAI)", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2026-12", "completion_date": "2032-01", "has_results": false, "last_update_posted_date": "2026-09-24", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07217496" }, { "nct_id": "NCT04700124", "title": "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Enfortumab vedotin (EV)", "type": "BIOLOGICAL" }, { "name": "RC + PLND", "type": "PROCEDURE" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 808, "start_date": "2021-04-21", "completion_date": "2028-05-18", "has_results": false, "last_update_posted_date": "2026-07-16", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Fullerton, California • Los Angeles, California + 19 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04700124" }, { "nct_id": "NCT05239624", "title": "Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2022-06-02", "completion_date": "2027-06", "has_results": false, "last_update_posted_date": "2026-10-13", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 10, "location_summary": "Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 7 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05239624" }, { "nct_id": "NCT03219333", "title": "A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Urologic Neoplasms", "Renal Pelvis Neoplasms", "Urothelial Cancer", "Ureteral Neoplasms", "Urethral Neoplasms" ], "interventions": [ { "name": "Enfortumab vedotin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 219, "start_date": "2017-10-08", "completion_date": "2023-07-28", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 54, "location_summary": "Anchorage, Alaska • Goodyear, Arizona • Phoenix, Arizona + 45 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03219333" }, { "nct_id": "NCT07815665", "title": "A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Metastatic Urothelial Carcinoma", "Metastatic Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "Ivonescimab Dose 1", "type": "DRUG" }, { "name": "enfortumab vedotin (EV)", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Ivonescimab Dose 2", "type": "DRUG" }, { "name": "Ivonescimab RP3D", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Summit Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 800, "start_date": "2026-09-10", "completion_date": "2030-12-31", "has_results": false, "last_update_posted_date": "2026-09-11", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 7, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT07815665" }, { "nct_id": "NCT05868265", "title": "A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Enfortumab Vedotin", "type": "DRUG" }, { "name": "Radical surgery", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2023-06-02", "completion_date": "2027-06-02", "has_results": false, "last_update_posted_date": "2026-08-06", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 8, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05868265" }, { "nct_id": "NCT07218380", "title": "A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Carcinoma, Transitional Cell", "Urinary Bladder Neoplasms", "Neoplasm Metastasis" ], "interventions": [ { "name": "Vepugratinib", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "EV", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 450, "start_date": "2025-12-12", "completion_date": "2033-05", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-10-21T18:40:56.877Z", "location_count": 64, "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Irvine, California + 48 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218380" } ] }